Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology …

R Passalacqua, C Caminiti, S Buti, C Porta… - Journal of …, 2014 - journals.lww.com
There is currently no standard therapy to reduce the recurrence rate after surgery for renal
cell carcinoma (RCC). The aim of this study was to assess efficacy and safety of adjuvant …

Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer

Y Shimanuki, K Takahashi, R Cui, S Hori, F Takahashi… - Lung, 2005 - Springer
Although vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9
are involved in angiogenesis of various cancers, clinical utility of preoperative serum …

Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells

S Han, N Sidell, PB Fisher, J Roman - Clinical Cancer Research, 2004 - AACR
Purpose: The peroxisome proliferator-activated receptor γ (PPARγ), a ligand-dependent
transcription factor belonging to the family of nuclear receptors, has been implicated in the …

Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src

Y Diao, X Ma, WL Min, S Lin, HF Kang, ZJ Dai, X Wang… - Cancer Letters, 2016 - Elsevier
Cisplatin and paclitaxel are considered to be the backbone of chemotherapy in lung
adenocarcinoma. These agents show pleiotropic effects on cell death. However, the precise …

Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer

T Ishiwata, K Takahashi, Y Shimanuki… - Anticancer …, 2005 - ar.iiarjournals.org
Background: Tenascin (Tn)-C is an extracellular matrix protein that is involved in tissue
interactions during fetal development and oncogenesis. However, the role of serum Tn-C in …

Interpreting trial results in light of conflicting evidence: a bayesian analysis of adjuvant chemotherapy for non–small-cell lung cancer

RA Miksad, M Gönen, TJ Lynch… - Journal of clinical …, 2009 - ascopubs.org
Purpose When successive randomized trials contradict prior evidence, clinicians may be
unsure how to evaluate them: Does accumulating evidence warrant changing practice? An …

[HTML][HTML] Adjuvant chemotherapy for non-small cell lung cancer

E Bria, F Cuppone, FL Cecere, M Milella… - Journal of Thoracic …, 2007 - Elsevier
Cisplatin must be considered the treatment standard for lung cancer chemotherapy,
whatever the disease setting, at least in the Western world. After the seminal meta-analysis …

Establishing an Interdisciplinary Oncology Team

N Levitan, M Armour, A Dowlati - Oncology: An Evidence-Based Approach, 2006 - Springer
In recent decades, cancer treatment has evolved from a purely surgical approach to the
complex coordination of sophisticated surgery, radiotherapy, and chemotherapy. The …

Essai randomisé de phase III de chimiothérapie adjuvante par CDDP/docetaxel versus CDDP/gemcitabine dans les cancers bronchiques non à petites cellules …

F Barlési, K Barrau, C Doddoli, S Morange… - Revue des maladies …, 2006 - Elsevier
Résumé Justificatif La chimiothérapie adjuvante à la chirurgie améliore la survie des
cancers bronchiques non à petites cellules (CNAPC) complètement réséqués. Méthodes …

[引用][C] Untersuchungen zum Einfluss von Applikationsrhythmen auf Wirksamkeit und Toxizität einer palliativen Chemotherapie bei Patienten mit fortgeschrittenem …

W Schütte - 2007 - Halle (Saale), Univ., Habil.-Schr …